Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma cells and subsequently induce their death, according to preclinical study findings.

19 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

Iron overload can lead to cytotoxicity, and it is a risk factor for diabetic peripheral neuropathy. However, the underlying mechanism remains unclear.

13 Mar 2014

Pretreatment with SSTF prevents cerebral ischemia-reperfusion injury, says study

Focal cerebral ischemia-reperfusion may lead to neuronal loss in the hippocampus, which is regarded as one of the basic pathological mechanisms underlying cognitive impairment.

11 Mar 2014

New study shows male hormones play important role; may enhance IVF therapy in women

Several fertility clinics across the country are beginning to administer testosterone, either through a patch or a gel on the skin, to increase the number of eggs produced by certain women undergoing in vitro fertilization (IVF).

5 Mar 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

Study identifies promising target for new drugs to treat lethal form of brain cancer

A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

27 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

Phasefocus’ KTP associate Dr Suman receives runners up spot for Cellular Heaven and Hell time-lapse video

Phase Focus Ltd (Phasefocus), the company that is revolutionizing microscopy and imaging with the Phasefocus Virtual Lens® technology, reports on the Celldance competition results held at the recent annual ASCB meeting. KTP associate, Dr Rakesh Suman, was runner up with his video entitled "Cellular Heaven & Hell."

From Phase Focus Limited 18 Feb 2014

Scientists explain why women with dense breast tissue at greater risk of developing breast cancer

Scientists from The University of Manchester working with IBM Research have identified a key biological mechanism that for the first time explains why women with dense breast tissue are at greater risk of developing breast cancer.

12 Feb 2014

Scientists identify twenty proteins specifically secreted by primary effusion lymphoma cell lines

Primary effusion lymphoma (PEL) is a rare B-cell neoplasm distinguished by its tendency to spread along the thin serous membranes that line body cavities without infiltrating or destroying nearby tissue.

10 Feb 2014

Scientists develop new approach to design drugs from genome sequence

In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.

10 Feb 2014

Researchers discover genetic function that helps "tumor suppressor" genes to prevent cancer

Researchers at Oregon State University have discovered a genetic function that helps one of the most important "tumor suppressor" genes to do its job and prevent cancer.

4 Feb 2014

RNAi-based screening offers MPM treatment hope

Research using RNA interference-based screening has identified several potential targets for the treatment of malignant pleural mesothelioma.

31 Jan 2014

Study points to gender-specific mechanisms of brain repair following oxygen deprivation

Physicians have long known that oxygen deprivation to the brain around the time of birth causes worse damage in boys than girls. Now a study by researchers from the Johns Hopkins Children’s Center conducted in mice reveals one possible reason behind this gender disparity and points to gender-specific mechanisms of brain repair following such injury.

31 Jan 2014

Phasefocus reports on new ptychography paper published in Nature Scientific Reports

Cell imaging often relies on synthetic or genetic fluorescent labels, to provide contrast which can be far from ideal for imaging cells in their in vivo state. We report on the biological application of a label-free, high contrast microscopy technique known as ptychography, in which the image producing step is transferred from the microscope lens to a high-speed phase retrieval algorithm.

From Phase Focus Limited 28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

New techniques simplify current test procedures for developing new medications

When developing new medications, biologists and pharma- cologists test different active ingredients and chemical compounds. The main purpose is to find out how biological cells react to these substances.

24 Jan 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Mesothelioma is a very aggressive cancer associated with asbestos exposure, which is usually diagnosed in an advanced stage. So far no therapeutic strategy has proven effective against this deadly cancer and the prognosis remains very poor with only few exceptions.

20 Jan 2014